Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Griffiths, C.
Right arrow Articles by Fisher, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griffiths, C.
Right arrow Articles by Fisher, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2002; 95: 635-636
© 2002 Association of Physicians

Correspondence

Abciximab-induced thrombocytopenia

C. Griffiths and M. Fisher

Division of Cardiology, University Hospital of Wales, Cardiff

The first 10% of the full text of this article appears below.

Sir,

Abciximab is a potent platelet glycoprotein IIb/IIIa receptor antagonist, currently indicated as adjunctive therapy during percutaneous coronary intervention and acute coronary syndromes. Potential future indications include acute myocardial infarction, peripheral arterial disease and ischaemic stroke, thus more widespread use is likely in the future. We present a case which highlights one of its . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?